期刊文献+

阿托伐他汀对冠状动脉血流缓慢患者冠状动脉血流储备的影响 被引量:23

Atrovastatin use and coronary flow reserve in patients with coronary slow flow
原文传递
导出
摘要 目的探讨冠状动脉血流缓慢患者冠状动脉血流储备(CFR)的改变以及阿托伐他汀对这类患者CFR的影响。方法入选有胸痛症状但冠状动脉造影结构正常的冠状动脉血流缓慢患者91例,分为治疗组(51例)和无治疗组(40例)。治疗组给予阿托伐他汀20mg治疗8周。另选26例冠状动脉造影正常且运动试验阴性的无心脏疾患者为正常对照组。治疗前后测定治疗组和无治疗组的血脂以及利用腺苷负荷超声记录左前降支远端血流频谱,并评价CFR。结果(1)冠状动脉血流缓慢者接受阿托伐他汀8周治疗后总胆固醇(TC)和低密度脂蛋白胆固醇(LDL—C)较无治疗组及正常对照组明显减低[TC:(3.83±0.80)mmol/L比(5.30±1.18)mmol/L和(5.32±1.17)mmoL/L,均P〈0.05;LDL—C:(2.26±0.64)mmol/L比(3.28±0.85)mmol/L和(3.30±0.82)mmol/L,均P〈0.05]。(2)给予阿托伐他汀前,治疗组与无治疗组CFR(分别为2.32±0.30和2.25±0.33)均低于正常对照组(3.15±0.34,P〈0.05);8周后,治疗组冠状动脉血流速度(CFV)[(26.06±3.22)cm/s]较无治疗组[(29.02±3.36)cm/s]及治疗前静息状态[(28.43±3.40)cm/s]低(均P〈0.05),最大冠状动脉扩张状态CFV高于无治疗组和对照组[分别为(77.63±8.96)、(65.17±7.22)和(64.58±6.26)cm/s,P〈0.05],CFR低于治疗前和无治疗组(分别为3.07±0.29、2.28±0.35和2.32±0.30,P〈0.05),且与正常对照组差异均无统计学意义。结论冠状动脉血流缓慢患者CFR明显减低,短期阿托伐他汀在调脂的同时可以有效改善其CFR。 Objective To investigate the impact of statin use on coronary flow reserve (CFR) in patients with slow coronary flow'. Methods A total of 91 patients with chest pain and coronary slow flow but normal coronary angiography were included in this study, patients were divided into statin group ( atrovastatin 20 mg/d for 8 weeks, n = 51 ) and non-statin group (n =40), 26 healthy subjects with normal angiography and negative exercise ECG test served as normal controls. Blood cholesterol was measured. Doppler coronary flow velocity and Doppler reserve measurement of distal left anterior descending were recorded at rest and adenosine infusion (140 μg · kg^-1 · min^-1) induced hyperemia state, CFR was calculated by the ratio of maximal hyperemia and baseline peak diastolic coronary flow velocity (hCFV and bCFV) before and after atrovastatin treatment. Results ( 1 ) Eight weeks later, total cholesterol and LDL-C levels were significantly lower in statin group than in non-statin group and control group [ TC (3.83 ± 0. 80) mmol/L vs. (5. 30 ±1.18 ) mmol/L vs. (5.32 ±1.17 ) mmol/L, P 〈 0. 05 ; LDL-C (2. 26 ±0. 64 ) mmol/L vs. ( 3.28 ±0. 85 ) mmol/L vs. (3.30 ±0. 82) mmol/L,P 〈0. 05]. (2) Baseline CFR levels were significantly lower in statin group and non-statin group than that in control group (2. 32 ±0. 30 vs. 2. 25 ±0. 33 vs. 3.15 ±0. 34, P 〈 0. 05 ). Compared with non-statin group and statin group before treatment, 8 weeks statin treatment was associated with reduced bCFV [ (26.06 ±3.22) cm/s vs. (29. 02 ±3.36) cm/s and (26. 06 ±3.22) cm/s vs. (28.43 ±3.40) cm/s,P 〈 0. 05 ], increased hCFV [ (77.63 ±8.96) cm/s vs. (65.17 ± 7.22) cm/s and (77. 63 ±8.96) cm/s vs. (64. 58 ±6. 26) cm/s,P 〈 0. 05 ] and increased CFR (3.07 ±0. 29 vs.2.28±0.35 and 3.07 ±0.29 vs. 2.32 ±0.30,P 〈0.05). bCFV, hCFV and CFR of statin group post treatment were similar to those of controls ( P 〉 0. 05 ). Conclusion Patients with coronary slow flow were associated with lower CFR which could be significantly improved by statin therapy.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2010年第2期143-146,共4页 Chinese Journal of Cardiology
关键词 冠状动脉循环 降血脂药 血流储备分数 心肌 Coronary circulation Antilipemic agents Fractional flow reserve,myocardial
  • 相关文献

参考文献14

  • 1De Bruyne B, Hersbach F, Pijls NH, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "normal" coronary angiography. Circulation, 2001, 104 : 2401- 2406.
  • 2Beltrame ,IF, Limaye SB, Horowitz JD. The coronary slow flow phenomenon- a new coronary microvascular disorder. Cardiology, 2002, 97: 197-202.
  • 3Dimitrow PP. Transthoracic Doppler echocardiography-noninvasive diagnostic window for coronary flow reserve assessment. Cardiovasc Ultrasound, 2003, 1:4.
  • 4Erdogan D, Gullu H, Caliskan M, et al. Coronary flow reserve is preserved in white-coat hypertension. Heart, 2006, 92 : 1109- 1112.
  • 5Erdogan D, Caliskan M, Gullu H, et al. Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis, 2007, 191 : 168-174.
  • 6Beltrame JF, Limaye SB, Wuttle RD, et al. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J, 2003, 146: 84-90.
  • 7Camsari A, Ozcan T, Ozer C, et al. Carotid artery intima-media thichness correlates with intravascular ultrasound parameters in patients with slow coronary flow. Atherosclerosis, 2008, 200: 310-314.
  • 8Sezgin AT, Sigirci A, Barutcu I, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis, 2003, 14 : 155-161.
  • 9Caliskan M, Erdogan D, Gullu H, et al. Effects of atrovastatin on coronary flow reserve in patients with slow coronary flow. Clin Cardiol, 2007, 30: 475479.
  • 10刘艳红,张梅,刘玲梅,周欣,焦占全,李玉明,庞伟.短期应用辛伐他汀对大鼠缺血再灌注后心肌无复流的影响及其潜在机制[J].中华心血管病杂志,2008,36(8):729-734. 被引量:13

二级参考文献17

  • 1Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no fellow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol, 2002, 283 : 1099-1107.
  • 2Celik T, Kurasaklioglu H, Iyisoy A, et al. The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction. Coron Artery Dis, 2005,16 : 321-326.
  • 3Pasceri V, Patti G,Nusca Aiet al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty ) study. Circulation, 2004,110 : 674-678.
  • 4Tavackoli S, Ashitkov T, Hu ZY, et al. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis, 2004,15 : 53-58.
  • 5Patti G, Pasceri V, Colonna G, et aL Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized triaL J Am Coil Cardiol, 2007, 49: 1272-1278.
  • 6Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol, 2005, 96: 611-616.
  • 7Lefer AM, Campbell B,Shin YK,et al. Simvastatin preserves the ischemic-reperfused myocardium in nornaocholesterolemic rat hearts. Circulation, 1999,100 : 178-184.
  • 8Rabelink TJ, Luscher TF. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vase Biol, 2006, 26: 267-271.
  • 9Becker BF, Kupatt C,Massoudy P,et al. Reactive oxygen species and nitric oxide in myocardial ischemia and reperfusion. Z Kardiol, 2000, 89 Suppl 9: IX/88-91.
  • 10Kis A, Yellon DM, Baxter GF. Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol, 2003,138 : 894-900.

共引文献12

同被引文献250

引证文献23

二级引证文献152

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部